MA
DNTH icon

Montag & Associates’s Dianthus Therapeutics DNTH Stock Holding History

Montag & Associates’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$355 – 1018
2025
Q3 		$355 Buy
+9
New +$230 ﹤0.01% 1102

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Montag & Associates's DNTH Position: Q4 2025 in Review

Montag & Associates sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 9 shares — an estimated $355 sold.

Montag & Associates first reported a position in DNTH in Q3 2025 and held it in 1 quarter. The position peaked at $355 in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Montag & Associates reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 9 Dianthus Therapeutics shares in Q4 2025, an estimated $355.
  • Montag & Associates first reported a position in Dianthus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Dianthus Therapeutics position peaked at $355 in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.